0001214659-18-001759.txt : 20180302 0001214659-18-001759.hdr.sgml : 20180302 20180302180818 ACCESSION NUMBER: 0001214659-18-001759 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180301 FILED AS OF DATE: 20180302 DATE AS OF CHANGE: 20180302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donadio Jamie A CENTRAL INDEX KEY: 0001579771 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 18663781 MAIL ADDRESS: STREET 1: C/O MIRATI THERAPEUTICS, INC. STREET 2: 9393 TOWNE CENTRE DRIVE, STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-41228.xml PRIMARY DOCUMENT X0306 4 2018-03-01 0001576263 Mirati Therapeutics, Inc. MRTX 0001579771 Donadio Jamie A C/O MIRATI THERAPEUTICS, INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 false true false false Sr. VP, CFO Common Stock 2018-03-01 4 M false 9375 5.5 A 9375 D Common Stock 2018-03-01 4 M false 12500 5.4 A 21875 D Common Stock 2018-03-01 4 M false 30000 7.3 A 51875 D Common Stock 2018-03-01 4 S false 25600 26.7779 D 26275 D Common Stock 2018-03-01 4 S false 25775 27.4526 D 500 D Common Stock 2018-03-01 4 S false 500 28.08 D 0 D Employee Stock Option (Right to Buy) 5.5 2018-03-01 4 M false 9375 0 D 2026-10-26 Common Stock 9375 20625 D Employee Stock Option (Right to Buy) 5.4 2018-03-01 4 M false 12500 0 D 2027-01-25 Common Stock 12500 37500 D Employee Stock Option (Right to Buy) 7.30 2018-03-01 4 M false 30000 0 D 2020-03-19 Common Stock 30000 0 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017. 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date. This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Jamie Donadio 2018-03-02